Use of octreotide in the treatment of chylopericardium

作者：Szabados Eszter^*; Toth Kalman; Mezosi Emese

来源：Heart & Lung, 2011, 40(6): 574-575.

DOI：10.1016/j.hrtlng.2010.01.004

Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 x 100 mu g daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.

• 出版日期2011-12